MedTrace Logo

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

NCT00560235 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2015-10-28

Study results available
· View outcomes & findings →

Summary

Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors

Conditions

  • Ewing's Sarcoma Family of Tumors

Interventions

DRUG

CP-751,871

Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-03-31
Completion
2012-10-31

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • Chile
  • France
  • Germany
  • Israel
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560235 on ClinicalTrials.gov